SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

BridgeBio Oncology Therapeutics' Yong Ben to Resign as Chief Medical and Development Officer

BridgeBio Oncology Therapeutics said Yong Ben will resign as chief medical and development officer, effective January 8, 2027.Original SEC Filing: BridgeBio Oncology Therapeutics, Inc. [ BBOT ] - 8-K - Nov. 05, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying impor…

BBOT

Related stories